|
Fuso Pharmaceutical Industries, Ltd. is a pharmaceutical company that manufactures and sells medical drugs and medical machinery. Its primary business segment focuses on the production of injectable solutions, including intravenous fluids and dialysis agents for artificial kidneys, as well as the provision of contract manufacturing services for other pharmaceutical products. The company also operates a real estate segment for property leasing. Fuso Pharmaceutical Industries serves the healthcare sector by supplying essential medical supplies and equipment to the market. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage fuso-pharm.co.jp |
| Sector Healthcare | IR page fuso-pharm.co.jp | |
|
Tags
intravenous fluids, dialysis agents, injectable solutions, medical machinery, contract manufacturing, real estate leasing
|
Press page fuso-pharm.co.jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 20.783B |
| Market cap (USD) | $ 129.896M |
| P/E | 8.45 |
| PEG | 1.08 |
| P/BV | 0.57 |
| P/S | 0.33 |
| P/OCF | 3.03 |
| P/FCF | 4.17 |
| Dividend yield | 4.1% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 5.9% |
| ROI | 3.2% |
| ROIC | 3.5% |
| Profit margin | 3.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 7.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 4 |
| Quality score | 38.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.307B | 60.563B | 55.407B | 51.015B | 49.632B | 49.251B | 46.902B | 46.074B | 45.9B | 46.782B | 45.752B | 47.042B | 49.098B | 48.612B |
| Net profit | 2.011B | -3.288B | 1.377B | 1.605B | 1.483B | 1.607B | 707M | 894M | 970M | 861M | 10M | 340M | 1.979B | 4.871B |
| Free cash flow | -7.883B | -6.403B | -2.961B | 1.279B | 2.011B | 2.02B | 3.224B | -267M | -297M | 38M | -3.195B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 2.356K | 2.208K | 2.208K | 1.995K | 2.181K | 2.546K | 2.095K | 2.529K | 2.828K | 2.809K | 2.606K | 3.112K | 3.63K | 4.143K |
| Price performance 12m | 0.07 | 0 | 0.11 | -0.09 | -0.14 | 0.22 | -0.17 | -0.11 | 0.01 | 0.08 | -0.16 | -0.14 | -0.12 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 21.4B | 22B | 22.1B | 20.4B | 239M | 302M | 21.7B | 24.3B | 26.5B | 26.9B |
| ↳ YoY growth | +3.5% | +2.9% | +0.4% | -7.5% | -98.8% | +26.4% | +7,099.0% | +11.9% | +8.9% | +1.5% |
| ↳ 5y CAGR | -59.0% | -57.3% | -0.2% | +2.0% | +5.4% | +157.2% | ||||
| Borrowings, current (JPY) | 6.02B | 6.61B | 6.54B | 6.51B | 6.2B | 5.94B | 5.66B | 5.7B | 18.8B | 26.6B |
| Borrowings, non-current (JPY) | 8.29B | 8.91B | 9.39B | 8.25B | 6.64B | 5.76B | 5.75B | 7.02B | 2.46B | 1.86B |
| Bonds payable (JPY) | 114M | 38M | — | — | — | — | — | — | — | — |
| Lease liabilities (JPY) | 7M | 3M | 4M | 1M | 2M | 1M | — | — | — | — |
| Cash and deposits (JPY) | 4.95B | 5.46B | 5.73B | 7.27B | 7.07B | 7.35B | 8.01B | 5.12B | 6.26B | 4.85B |
| Intangible assets (JPY) | 509M | 1.01B | 753M | 518M | 323M | 453M | 329M | 600M | 1.51B | 1.35B |
| Net debt (borrowings + leases - cash) (JPY) | 9.37B | 10.1B | 10.2B | 7.48B | 5.76B | 4.35B | 3.4B | 7.6B | 15B | 23.6B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 1.88B | 1.42B | 2.05B | 5.73B | 3.23B | 3.5B | 2.85B | 627M | -3.31B | -6.22B |
| Purchases of property, plant and equipment (JPY) | -1.84B | -961M | -2.3B | -2.49B | -1.18B | -1.41B | -1.55B | -3.25B | -2.12B | -1.27B |
| Purchases of intangible assets (JPY) | -318M | -756M | -22M | -10M | -28M | -79M | -28M | -343M | -976M | — |
| Change in receivables (cash effect) (JPY) | -725M | -620M | -84M | 1.66B | -983M | 231M | -588M | -2.59B | -2.16B | — |
| Change in inventories (cash effect) (JPY) | -731M | 96M | -654M | 280M | -712M | 213M | -1.94B | -1.75B | -739M | — |
| Change in payables (cash effect) (JPY) | 501M | -529M | 416M | 634M | -325M | 715M | 1.45B | 1.75B | -7.8B | — |
| Dividends paid (cash effect) (JPY) | -717M | -706M | -700M | -613M | -525M | -525M | -525M | -645M | -638M | — |
| Share buybacks (cash effect) (JPY) | -282M | -427M | -6M | -2M | -4M | -2M | -3M | -652M | -4M | — |
| Interest paid (cash effect) (JPY) | -225M | -217M | -229M | -234M | -195M | -176M | -166M | -170M | -143M | — |
| Income taxes paid (cash effect) (JPY) | -99M | -584M | -348M | -374M | -190M | -979M | -239M | -578M | -374M | — |
| Operating cash flow before change in receivables (JPY) | 2.6B | 2.04B | 2.14B | 4.07B | 4.21B | 3.27B | 3.44B | 3.21B | -1.14B | — |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 38M | -297M | -267M | 3.22B | 2.02B | 2.01B | 1.28B | -2.96B | -6.4B | — |
| Income detail | ||||||||||
| Research and development expense (JPY) | 2.26B | 2.01B | 1.76B | 1.41B | 1.46B | 1.44B | 1.35B | 1.47B | 1.72B | 2.01B |
| ↳ 5y CAGR | -7.9% | -8.6% | -7.6% | -3.6% | +4.0% | +6.6% | ||||
| Provision for credit losses (JPY) | — | — | — | — | 216M | -216M | — | — | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | 2.1% | 79.9% | — | — | — | — |
| Reported | Jun 26, 2018 | Jun 26, 2018 | Jun 26, 2020 | Jun 29, 2021 | Jun 29, 2022 | Jun 29, 2023 | Jun 25, 2024 | Jun 24, 2025 | Jun 23, 2026 | Nov 11, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Fuso Pharmaceutical Industries, Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.